Compare Altria Group Inc (MO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Altria Group (MO) trades at $71.89, up 3.61% with a bullish technical signal from moving averages. The company maintains strong profitability with 39% net margins and generates robust operating cash flow of $9.29B, supporting its 6.6% dividend yield. Recent earnings show mixed results with one beat and two misses in the last four quarters. The stock trades below analyst consensus target of $69.71 despite negative shareholder equity of -$2.24B due to high debt levels.

MO offers income investors an attractive dividend yield but faces structural challenges including declining cigarette volumes and regulatory uncertainty. Analyst consensus remains positive with 61.5% buy ratings, though concerns persist about the sustainability of dividend payments given the company's negative equity position and competitive pressures in smoke-free alternatives.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.